Phytoestrogens: Science, evidence, and advice for breast cancer patients

Journal of the Society for Integrative Oncology

Volumn 8, Issue 1, 2010, Pages 20-30

  Deng, Gary ^a   Davatgarzadeh, Arousha ^a   Yeung, Simon ^a   Cassileth, Barrie ^a  

^a Memorial Sloun Kettering Cancer Center   (United States)

Author keywords

Botanicals; Breast cancer; Diet; Nutrition; Phytoestrogen

Indexed keywords

COUMESTAN DERIVATIVE; COUMESTROL; DAIDZEIN; ENTEROLACTONE; ESTRADIOL; ESTROGEN RECEPTOR; GENISTEIN; ISOFLAVONE DERIVATIVE; LIGNAN; OMEGA 3 FATTY ACID; PHYTOESTROGEN; PRIMROSE OIL; QUERCETIN; RESVERATROL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOYBEAN PROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG; PLANT MEDICINAL PRODUCT;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER PATIENT; CLINICAL PRACTICE; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG HALF LIFE; DRUG STRUCTURE; EVIDENCE BASED PRACTICE; FOOD DRUG INTERACTION; GENE EXPRESSION; GLYCYRRHIZA; HOPS; HUMAN; LINSEED; NONHUMAN; PRACTICE GUIDELINE; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; RED CLOVER; REVIEW; RISK BENEFIT ANALYSIS; SOYBEAN; STRUCTURE ANALYSIS; TRANSCRIPTION INITIATION; YAM; ANIMAL; BREAST NEOPLASMS; DIETARY SUPPLEMENT; SOY FOOD;

ANIMALS; BREAST NEOPLASMS; DIETARY SUPPLEMENTS; HUMANS; ISOFLAVONES; PHYTOESTROGENS; PLANT PREPARATIONS; RECEPTORS, ESTROGEN; SOY FOODS;

EID: 77349117336     PISSN: 1715894X     EISSN: None     Source Type: Journal    
DOI: 10.2310/7200.2009.0016     Document Type: Review

References (110)

1. Duffy C, Cyr M. Phytoestrogens: potential benefits and implications for breast cancer survivors. J Womens Health (Larchmt) 2003;12:617-31.
2. Duffy C, Perez K, Partridge A. Implications of phytoestrogen intake for breast cancer. CA Cancer J Clin 2007;57:260-77.
3. Touillaud MS, Pillow PC, Jakovljevic J, et al. Effect of dietary intake of phytoestrogens on estrogen receptor status in premenopausal women with breast cancer. Nutr Cancer 2005;51:162-9.
4. Dahlman-Wright K, Cavailles V, Fuqua SA, et al. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 2006;58:773-81.
5. Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets? Physiol Rev 2007;87:905-31.
6. Gotteland M, Desauty G, Delarue JC, et al. Human estrogen receptor messenger RNA variants in both normal and tumor breast tissues. Mol Cell Endocrinol 1995;112:1-13.
7. Zhao C, Lam EW, Sunters A, et al. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 23 2003;22:7600-6.
8. Iwao K, Miyoshi Y, Egawa C, et al. Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers. Int J Cancer 2000;88:733-6.
9. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321-44.
10. Jepsen K, Hermanson O, Onami TM, et al. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 2000;102:753-63.
11. Fitzpatrick LA. Selective estrogen receptor modulators and phytoestrogens: new therapies for the postmenopausal women. Mayo Clin Proc 1999;74:601-7.
12. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-29.
13. Turner JV, Agatonovic-Kustrin S, Glass BD. Molecular aspects of phytoestrogen selective binding at estrogen receptors. J Pharm Sci 2007;96:1879-85.
14. Mueller SO. Xenoestrogens: mechanisms of action and detection methods. Anal Bioanal Chem 2004;378:582-7.
15. Diel P, Olff S, Schmidt S, Michna H. Molecular identification of potential selective estrogen receptor modulator (SERM) like properties of phytoestrogens in the human breast cancer cell line MCF-7. Planta Med 2001;67:510-4.
16. Yildiz F. Phytoestrogens in functional foods. Taylor & Francis; 2005.
17. Kurzer MS, Xu X. Dietary phytoestrogens. Annu Rev Nutr 1997;17:353-81.
18. Setchell KD. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 1998; 68 (6 Suppl):1333S-46S.
19. Tempfer CB, Bentz EK, Leodolter S, et al. Phytoestrogens in clinical practice: a review of the literature. Fertil Steril 2007;87:1243-9.
20. Rice S, Whitehead SA. Phytoestrogens and breast cancer-promoters or protectors? Endocr Relat Cancer 2006;13:995-1015.
21. de Kleijn MJ, van der Schouw YT, Wilson PW, et al. Intake of dietary phytoestrogens is low in postmenopausal women in the United States: the Framingham study (1-4). J Nutr 2001;131:1826-32.
22. Fletcher RJ. Food sources of phyto-oestrogens and their precursors in Europe. Br J Nutr 2003; 89 Suppl 1:S39-43.
23. Boker LK, van der Schouw YT, De Kleijn MJ, et al. Intake of dietary phytoestrogens by Dutch women. J Nutr 2002;132:1319-28.
24. Mulligan AA, Welch AA, McTaggart AA, et al. Intakes and sources of soya foods and isoflavones in a UK population cohort study (EPIC-Norfolk). Eur J Clin Nutr 2007;61:248-54.
25. ValstaLM,KilkkinenA,MazurW,etal.Phyto-oestrogen database of foods and average intake in Finland. Br J Nutr 2003; 89 Suppl 1:S31-8.
26. Surh J, Kim MJ, Koh E, et al. Estimated intakes of isoflavones and coumestrol in Korean population. Int J Food Sci Nutr 2006;57:325-44.
27. Iwasaki M, Inoue M, Otani T, et al. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. J Clin Oncol 2008; 26:1677-83.
28. Liu Z, Saarinen NM, Thompson LU. Sesamin is one of the major precursors of mammalian lignans in sesame seed ( Sesamum indicum ) as observed in vitro and in rats. J Nutr 2006;136:906-12.
29. Pettersson H, Kiessling KH. Liquid chromatographic determination of the plant estrogens coumestrol and isoflavones in animal feed. J Assoc Off Anal Chem 1984;67:503-6.
30. Mazur W. Phytoestrogen content in foods. Baillieres Clin Endocrinol Metab 1998; 12:729-42.
31. Liggins J, Bluck LJ, Runswick S, et al. Daidzein and genistein contents of vegetables. Br J Nutr 2000;84:717-25.
32. Reinli K, Block G. Phytoestrogen content of foods-a compendium of literature values. Nutr Cancer 1996;26:123-48.
33. Knight DC, Eden JA. A review of the clinical effects of phytoestrogens. Obstet Gynecol 1996; 87(5 Pt 2): 897-904.
34. Thompson LU, Boucher BA, Liu Z, et al. Phytoestrogen content of foods consumed in Canada, including isoflavones, lignans, and coumestan. Nutr Cancer 2006;54:184-201.
35. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998;139:4252-63.
36. Setchell KD. Soy isoflavones-benefits and risks from nature's selective estrogen receptor modulators (SERMs). J Am Coll Nutr 2001;20(5 Suppl):354S-62S; discussion 381S-3S.
37. Adlercreutz H, Fotsis T, Watanabe S, et al. Determination of lignans and isoflavonoids in plasma by isotope dilution gas chromatography-mass spectrometry. Cancer Detect Prev 1994;18:259-71.
38. Setchell KD, Brown NM, Desai PB, et al. Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. J Nutr 2003;133:1027-35.
39. Piazza C, Privitera MG, Melilli B, et al. Influence of inulin on plasma isoflavone concentrations in healthy postmenopausal women. Am J Clin Nutr 2007;86:775-80.
40. Gu L, Laly M, Chang HC, et al. Isoflavone conjugates are underestimated in tissues using enzymatic hydrolysis. J Agric Food Chem 2005;53:6858-63.
41. Lampe JW, Nishino Y, Ray RM, et al. Plasma isoflavones and fibrocystic breast conditions and breast cancer among women in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2007;16:2579-86.
42. Cline JM, Hughes CL Jr. Phytochemicals for the prevention of breast and endometrial cancer. Cancer Treat Res 1998;94:107-34.
43. Gikas PD, Mokbel K. Phytoestrogens and the risk of breast cancer: a review of the literature. Int J Fertil Womens Med 2005;50:250-8.
44. Michels KB, Mohllajee AP, Roset-Bahmanyar E, et al. Diet and breast cancer: a review of the prospective observational studies. Cancer 2007;109(12 Suppl):2712-49.
45. Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. Br J Cancer 2008;98:9-14.
46. Potter SM, Baum JA, Teng H, et al. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998;68(6 Suppl):1375S-9S.
47. Kreijkamp-Kaspers S, Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. JAMA 2004;292:65-74.
48. Allen JK, Becker DM, Kwiterovich PO, et al. Effect of soy protein-containing isoflavones on lipoproteins in postmenopausal women. Menopause 2007;14:106-14.
49. Kokubo Y, Iso H, Ishihara J, et al. Association of dietary intake of soy, beans, and isoflavones with risk of cerebral and myocardial infarctions in Japanese populations: the Japan Public Health Center-based (JPHC) study cohort I. Circulation 2007;116:2553-62.
50. Unfer V, Casini ML, Costabile L, et al. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril 2004;82:145-8 , quiz 265.
51. Messina M, McCaskill-Stevens W, Lampe JW. Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst 2006;98:1275-84.
52. Miodini P, Fioravanti L, Di Fronzo G, Cappelletti V. The two phyto-oestrogens genistein and quercetin exert different effects on oestrogen receptor function. Br J Cancer 1999;80:1150-5.
53. Le Bail JC, Champavier Y, Chulia AJ, Habrioux G. Effects of phytoestrogens on aromatase, 3beta and 17beta-hydroxysteroid dehydrogenase activities and human breast cancer cells. Life Sci 2000;66:1281-91.
54. Dip R, Lenz S, Antignac JP, et al. Global gene expression profiles induced by phytoestrogens in human breast cancer cells. Endocr Relat Cancer 2008;15:161-73.
55. Messina MJ, Loprinzi CL. Soy for breast cancer survivors: a critical review of the literature. J Nutr 2001; 131 (11 Suppl): 3095S-108S.
56. Ju YH, Doerge DR, Allred KF, et al. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002;62:2474-7.
57. Ju YH, Doerge DR, Woodling KA, et al. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogendependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis 2008;29:2162-8.
58. Schwartz JA, Liu G, Brooks SC. Genistein-mediated attenuation of tamoxifen-induced antagonism from estrogen receptor-regulated genes. Biochem Biophys Res Commun 1998;253:38-43.
59. Zava DT, Duwe G. Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr Cancer 1997;27:31-40.
60. Sugimoto E, Yamaguchi M. Anabolic effect of genistein in osteoblastic MC3T3-E1 cells. Int J Mol Med 2000;5:515-20.
61. Gotoh T, Yamada K, Ito A, et al. Chemoprevention of N-nitroso-N- methylurea-induced rat mammary cancer by miso and tamoxifen, alone and in combination. Jpn J Cancer Res 1998;89:487-95.
62. Cheng G, Wilczek B, Warner M, et al. Isoflavone treatment for acute menopausal symptoms. Menopause 2007;14(3 Pt 1):468-73.
63. Sartippour MR, Rao JY, Apple S, et al. A pilot clinical study of short-term isoflavone supplements in breast cancer patients. Nutr Cancer 2004;49:59-65.
64. Hargreaves DF, Potten CS, Harding C, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab 1999;84:4017-24.
65. Maskarinec G, Franke AA, Williams AE, et al. Effects of a 2-year randomized soy intervention on sex hormone levels in premenopausal women. Cancer Epidemiol Biomarkers Prev 2004; 13(11 Pt 1):1736-44.
66. Maskarinec G, Williams AE, Carlin L. Mammographic densities in a one-year isoflavone intervention. Eur J Cancer Prev 2003;12:165-9.
67. Messina MJ, Wood CE. Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J 2008;7:17.
68. Vachon CM, van Gils CH, Sellers TA, et al. Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res 2007;9:217.
69. Patella A, Marziani R, Schippa A, et al. Breast density changes associated with hormone replacement therapy in postmenopausal women. Effects on the specificity and sensitivity of mammographic screening. Eur J Gynaecol Oncol 2005;26:485-90.
70. Booth NL, Overk CR, Yao P, et al. Seasonal variation of red clover (Trifolium pratense L., Fabaceae) isoflavones and estrogenic activity. J Agric Food Chem 2006;54:1277-82.
71. Powles TJ, Howell A, Evans DG, et al. Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. Menopause Int 2008;14:6-12.
72. Komesaroff PA, Black CV, Cable V, Sudhir K. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric 2001;4:144-50.
73. Pitkin J. Red clover isoflavones in practice: a clinician's view. J Br Menopause Soc 2004; 10 Suppl 1: 7-12.
74. Lukaczer D, Darland G, Tripp M, et al. Clinical effects of a proprietary combination isoflavone nutritional supplement in menopausal women: a pilot trial. Altern Ther Health Med 2005;11:60-5.
75. Jeon GC, Park MS, Yoon DY, et al. Antitumor activity of spinasterol isolated from Pueraria roots . Exp Mol Med 2005;37:111-20.
76. Lampe JW, Atkinson C, Hullar MA. Assessing exposure to lignans and their metabolites in humans. J AOAC Int 2006;89:1174-81.
77. Hutchins AM, Martini MC, Olson BA, et al. Flaxseed influences urinary lignan excretion in a dose-dependent manner in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2000;9:1113-8.
78. Penttinen P, Jaehrling J, Damdimopoulos AE, et al. Diet-derived polyphenol metabolite enterolactone is a tissue-specific estrogen receptor activator. Endocrinology 2007;148:4875-86.
79. Kilkkinen A, Stumpf K, Pietinen P, et al. Determinants of serum enterolactone concentration. Am J Clin Nutr 2001;73:1094-100.
80. Adlercreutz H, Fotsis T, Lampe J, et al. Quantitative determination of lignans and isoflavonoids in plasma of omnivorous and vegetarian women by isotope dilution gas chromatography-mass spectrometry. Scand J Clin Lab Invest Suppl 1993;215:5-18.
81. Wang C, Kurzer MS. Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutr Cancer 1997;28:236-47.
82. Welshons WV, Murphy CS, Koch R, et al. Stimulation of breast cancer cells in vitro by the environmental estrogen enterolactone and the phytoestrogen equol. Breast Cancer Res Treat 1987;10:169-75.
83. Chen J, Hui E, Ip T, Thompson LU. Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (mcf-7) in nude mice. Clin Cancer Res 2004;10:7703-11.
84. Power KA, Thompson LU. Can the combination of flaxseed and its lignans with soy and its isoflavones reduce the growth stimulatory effect of soy and its isoflavones on established breast cancer? Mol Nutr Food Res 2007;51:845-56.
85. Chen J, Stavro PM, Thompson LU. Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor. Nutr Cancer 2002;43:187-92.
86. Chen J, Power KA, Mann J, et al. Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways. Nutr Cancer 2007;58:162-70.
87. Bergman Jungestrom M, Thompson LU, Dabrosin C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin Cancer Res 2007;13:1061-7.
88. Basch E, Bent S, Collins J, et al. Flax and flaxseed oil ( Linum usitatissimum ): a review by the Natural Standard Research Collaboration. J Soc Integr Oncol 2007;5:92-105.
89. Eliasson C, Kamal-Eldin A, Andersson R, Aman P. High-performance liquid chromatographic analysis of secoisolariciresinol diglucoside and hydroxycinnamic acid glucosides in flaxseed by alkaline extraction. J Chromatogr A 2003;1012:151-9.
90. Benghuzzi H, Tucci M, Eckie R, Hughes J. The effects of sustained delivery of diosgenin on the adrenal gland of female rats. Biomed Sci Instrum 2003;39:335-40.
91. Aradhana, Rao AR, Kale RK. Diosgenin-a growth stimulator of mammary gland of ovariectomized mouse. Indian J Exp Biol 1992; 30:367-70.
92. Schulz V, Hänsel R, Blumenthal M, Tyler VE. Rational phytotherapy: a physician's guide to herbal medicine. New York: Springer; 2001.
93. Carroll DG. Nonhormonal therapies for hot flashes in menopause. Am Fam Physician 2006;73:457-64.
94. Liu J, Burdette JE, Xu H, et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem 2001;49:2472-9.
95. Lau CB, Ho TC, Chan TW, Kim SC. Use of dong quai ( Angelica sinensis ) to treat peri- or postmenopausal symptoms in women with breast cancer: is it appropriate? Menopause 2005;12:734-40.
96. Goh SY, Loh KC. Gynaecomastia and the herbal tonic "dong quai." Singapore Med J 2001;42:115-6.
97. Hu Y, Hou TT, Zhang QY, et al. Evaluation of the estrogenic activity of the constituents in the fruits of Vitex rotundifolia L. for the potential treatment of premenstrual syndrome. J Pharm Pharmacol 2007;59:1307-12.
98. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ 2001;322:134-7.
99. Liu J, Burdette JE, Sun Y, et al. Isolation of linoleic acid as an estrogenic compound from the fruits of Vitex agnus-castus L. (chaste-berry). Phytomedicine 2004;11:18-23.
100. Rimoldi G, Christoffel J, Wuttke W. Morphologic changes induced by oral long-term treatment with 8-prenylnaringenin in the uterus, vagina, and mammary gland of castrated rats. Menopause 2006;13:669-77.
101. Monteiro R, Faria A, Azevedo I, Calhau C. Modulation of breast cancer cell survival by aromatase inhibiting hop (Humulus lupulus L.) flavonoids. J Steroid Biochem Mol Biol 2007;105:124-30.
102. Jo EH, Hong HD, Ahn NC, et al. Modulations of the Bcl-2/Bax family were involved in the chemopreventive effects of licorice root (Glycyrrhiza uralensis Fisch) in MCF-7 human breast cancer cell. J Agric Food Chem 2004;52:1715-9.
103. Tamir S, Eizenberg M, Somjen D, et al. Estrogenlike activity of glabrene and other constituents isolated from licorice root. J Steroid Biochem Mol Biol 2001;78:291-8.
104. Ruhlen RL, Haubner J, Tracy JK, et al. Black cohosh does not exert an estrogenic effect on the breast. Nutr Cancer 2007;59:269-77.
105. Al-Akoum M, Dodin S, Akoum A. Synergistic cytotoxic effects of tamoxifen and black cohosh on MCF-7 and MDA-MB-231 human breast cancer cells: an in vitro study. Can J Physiol Pharmacol 2007;85:1153-9.
106. Gaube F, WolflS, Pusch L, et al. Gene expression profiling reveals effects of Cimicifuga racemosa (L.) NUTT. (black cohosh) on the estrogen receptor positive human breast cancer cell line MCF-7. BMC Pharmacol 2007;7:11.
107. Einbond LS, Wen-Cai Y, He K, et al. Growth inhibitory activity of extracts and compounds from Cimicifuga species on human breast cancer cells. Phytomedicine 2008;15(6-7):504-11. Epub 2007 Nov 5.
108. Walji R,Boon H,GunsE,etal.Black cohosh(Cimicifuga racemosa [L.] Nutt.): safety and efficacy for cancer patients. Support Care Cancer 2007;15:913-21.
109. Antoine C, Liebens F, Carly B, et al. Safety of alternative treatments for menopausal symptoms after breast cancer: a qualitative systematic review. Climacteric 2007;10:23-6.
110. Rock E, DeMichele A. Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors. J Nutr 2003;133(11 Suppl 1): 3785S-93S.